Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance".

Serebruany V, Cherala G, Williams C, Surigin S, Booze C, Kuliczkowski W, Atar D.

Am Heart J. 2009 Dec;158(6):925-32. doi: 10.1016/j.ahj.2009.10.012.

PMID:
19958858
2.

Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.

Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA, Brandt JT, Sugidachi A, Siegbahn A, Wallentin L.

J Am Coll Cardiol. 2008 Dec 9;52(24):1968-77. doi: 10.1016/j.jacc.2008.07.068.

3.

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.

Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ.

Am Heart J. 2007 Jan;153(1):66.e9-16.

PMID:
17174640
4.

Determination of clopidogrel main metabolite in plasma: a useful tool for monitoring therapy?

Mani H, Toennes SW, Linnemann B, Urbanek DA, Schwonberg J, Kauert GF, Lindhoff-Last E.

Ther Drug Monit. 2008 Feb;30(1):84-9. doi: 10.1097/FTD.0b013e31815c13fd.

PMID:
18223467
5.

Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.

Payne CD, Li YG, Small DS, Ernest CS 2nd, Farid NA, Jakubowski JA, Brandt JT, Salazar DE, Winters KJ.

J Cardiovasc Pharmacol. 2007 Nov;50(5):555-62.

PMID:
18030066
7.

Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Motovska Z, Kala P.

Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Review.

PMID:
19281914
8.

Variability in platelet responsiveness to clopidogrel among 544 individuals.

Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ.

J Am Coll Cardiol. 2005 Jan 18;45(2):246-51.

9.

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.

Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ.

J Thromb Haemost. 2007 Dec;5(12):2429-36. Epub 2007 Sep 26.

10.

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.

Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A.

Eur Heart J. 2008 Jan;29(1):21-30. Epub 2007 Nov 30.

11.

Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy.

Bal Dit Sollier C, Berge N, Boval B, Hovsepian L, Drouet L.

Thromb Haemost. 2009 Jan;101(1):116-22.

PMID:
19132197
12.
13.

Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease.

Perneby C, Wallén NH, Hofman-Bang C, Tornvall P, Ivert T, Li N, Hjemdahl P.

Thromb Haemost. 2007 Dec;98(6):1316-22.

PMID:
18064330
14.

ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.

Schäfer A, Weinberger S, Flierl U, Eigenthaler M, Störk S, Walter U, Ertl G, Bauersachs J.

Thromb Haemost. 2008 Oct;100(4):618-25.

PMID:
18841284
15.

Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.

Ernest CS 2nd, Small DS, Rohatagi S, Salazar DE, Wallentin L, Winters KJ, Wrishko RE.

J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):593-618. doi: 10.1007/s10928-008-9103-7. Epub 2008 Nov 21.

PMID:
19023649
16.
17.

How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.

Neubauer H, Lask S, Engelhardt A, Mügge A.

Thromb Haemost. 2008 Feb;99(2):357-62. doi: 10.1160/TH07-10-0624.

PMID:
18278186
18.

Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications.

Serebruany V, Rao SV, Silva MA, Donovan JL, Kannan AO, Makarov L, Goto S, Atar D.

Eur Heart J. 2010 Jan;31(2):227-35. doi: 10.1093/eurheartj/ehp434. Epub 2009 Oct 23.

19.

Comparison of collagen versus adenosine diphosphate in detecting antiplatelet effect in patients with coronary artery disease.

Li J, Jian Z, Huang L, Guo H, Huang J, Qian D, Fu W, Li A, Song Y.

Biomed Pharmacother. 2009 Sep;63(8):608-12. doi: 10.1016/j.biopha.2008.10.004. Epub 2008 Oct 31.

PMID:
19019624
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk